Literature DB >> 12540065

The clinical spectrum of fibrocalculous pancreatic diabetes in north India.

N Mittal1, R Mehrotra, G Agarwal, G Choudhuri, S Sikora, E Bhatia.   

Abstract

BACKGROUND: Fibrocalculous pancreatic diabetes (FCPD) is a secondary form of diabetes, unique to tropical countries. In earlier reports, patients with FCPD had severe insulin-requiring diabetes, malnutrition and a dismal prognosis. With Improvements in nutrition and medical care, the presentation and prognosis of FCPD may have changed. We report on the clinical profile and prognosis of a cohort of FCPD patients from north India and compare our findings with earlier reports.
METHODS: Eighty consecutive FCPD patients who presented to the Diabetes, Gastroenterology and Surgical Gastroenterology services were evaluated for their nutritional status, clinical presentation, beta-cell function (fasting C-peptide) and exocrine function (faecal chymotrypsin). All patients diagnosed between 1994 and 2000 (n = 32) were followed prospectively for weight gain and glycaemic control.
RESULTS: Only 55% of FCPD patients had a low body mass index (< 18 kg/m2). At the time of diagnosis of diabetes, only 26 (33%) patients presented with severe insulin-requiring diabetes; these patients were younger [23.7 (8.3) years v. 28.7 (10.6) years, p = 0.04], and had higher haemoglobin A1c [9.7 (3.8)% v. 7.3 (2.6)%, p = 0.005] than those requiring diet control or oral hypoglycaemic agents. FCPD patients had a wide range of fasting serum C-peptide (0.03-0.76 nmol/L). C-peptide was negatively associated with increasing duration of diabetes (r = -0.48, p = 0.001), but there was no correlation with faecal chymotrypsin. On prospective follow up (mean 2.3 years), there was significant improvement in body mass index [19.4 (2.9) kg/m2 v. 17.0 (3.7) kg/m2, p < 0.01] and haemoglobin A,c [6.4 (1.6)% v. 8.0 (3.0)%, p < 0.001].
CONCLUSION: FCPD patients differed from those described in earlier reports in many respects, Including improved nutritional status, a wide range of 3cell function and a more favourable prognosis.

Entities:  

Mesh:

Year:  2002        PMID: 12540065

Source DB:  PubMed          Journal:  Natl Med J India        ISSN: 0970-258X            Impact factor:   0.537


  7 in total

1.  Absence of association between SPINK1 trypsin inhibitor mutations and Type 1 or 2 diabetes mellitus in India and Germany.

Authors:  E Bhatia; K Balasubramanium; J Rajeswari; O Kordonouri; H Witt; O Landt; P Simon; M M Lerch
Journal:  Diabetologia       Date:  2003-11-01       Impact factor: 10.122

2.  Comparison of CGM-Derived Measures of Glycemic Variability Between Pancreatogenic Diabetes and Type 2 Diabetes Mellitus.

Authors:  Channabasappa Shivaprasad; Yalamanchi Aiswarya; Shah Kejal; Atluri Sridevi; Biswas Anupam; Barure Ramdas; Kolla Gautham; Premchander Aarudhra
Journal:  J Diabetes Sci Technol       Date:  2019-07-07

Review 3.  Tropical chronic pancreatitis.

Authors:  K K Barman; G Premalatha; V Mohan
Journal:  Postgrad Med J       Date:  2003-11       Impact factor: 2.401

4.  Heterogeneity in the aetiology of diabetes mellitus in young adults: A prospective study from north India.

Authors:  Saroj Kumar Sahoo; Ghazala Zaidi; Valam Puthussery Vipin; Aaron Chapla; Nihal Thomas; Liping Yu; Pranjul Asthana; Eesh Bhatia
Journal:  Indian J Med Res       Date:  2019-04       Impact factor: 2.375

5.  Young-onset diabetes: An Indian perspective.

Authors:  Deep Dutta; Soumitra Ghosh
Journal:  Indian J Med Res       Date:  2019-04       Impact factor: 2.375

6.  The Clinical Spectrum of Fibrocalculous Pancreatic Diabetes in Kashmir Valley and Comparative Study of the Clinical Profile of Fibrocalculous Pancreatic Diabetes and Type 2 Diabetes Mellitus.

Authors:  Javaid Ahmad Bhat; Moomin Hussain Bhat; Raiz Ahmad Misgar; Mir Iftikhar Bashir; Arshad Iqbal Wani; Shariq Rashid Masoodi; Hamid Ashraf; Mona Sood
Journal:  Indian J Endocrinol Metab       Date:  2019 Sep-Oct

Review 7.  Genetic aspects of tropical calcific pancreatitis.

Authors:  Heiko Witt; Eesh Bhatia
Journal:  Rev Endocr Metab Disord       Date:  2008-09       Impact factor: 9.306

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.